Ganciclovir effectively prevents cytomegalovirus (CMV) disease in the first 100 days after
allogeneic hematopoietic stem cell transplantation (HSCT), but late-onset CMV disease is …

Allogeneic peripheral blood stem cell grafts contain about 10 times more T and B cells than
marrow grafts. Because these cells may survive in transplant recipients for a long time, …

There is intense interest in antibody immunity to coronaviruses. However, it is unknown if
coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this …

Previous studies have shown that detection of cytomegalovirus (CMV) DNA in plasma is less
sensitive than the antigenemia assay for CMV surveillance in blood. In 1,983 blood samples…

Reconstitution of cellular immunity by 3 months after hematopoietic stem cell transplantation
(HSCT) is a critical determinant of the long-term success of the transplantation. We …

Strategies to prevent active infection with certain double-stranded DNA (dsDNA) viruses
after allogeneic hematopoietic cell transplantation (HCT) are limited by incomplete …

Background: Optimal prevention of late cytomegalovirus (CMV) disease is poorly defined.
Objective: To compare valganciclovir prophylaxis with polymerase chain reaction–guided …

10.7554/eLife.26875.001 Viral variants that arise in the global influenza population begin
as de novo mutations in single infected hosts, but the evolutionary dynamics that transform …

Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive donors, …

Decreased cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation
(HCT) is associated with late CMV reactivation and increased mortality. Whether letermovir …